Eso, Y.; Nakano, S.; Mishima, M.; Arasawa, S.; Iguchi, E.; Nakamura, F.; Takeda, H.; Takai, A.; Takahashi, K.; Taura, K.;
et al. Dose Intensity/Body Surface Area Ratio is a Novel Marker Useful for Predicting Response to Lenvatinib against Hepatocellular Carcinoma. Cancers 2020, 12, 49.
https://doi.org/10.3390/cancers12010049
AMA Style
Eso Y, Nakano S, Mishima M, Arasawa S, Iguchi E, Nakamura F, Takeda H, Takai A, Takahashi K, Taura K,
et al. Dose Intensity/Body Surface Area Ratio is a Novel Marker Useful for Predicting Response to Lenvatinib against Hepatocellular Carcinoma. Cancers. 2020; 12(1):49.
https://doi.org/10.3390/cancers12010049
Chicago/Turabian Style
Eso, Yuji, Shigeharu Nakano, Masako Mishima, Soichi Arasawa, Eriko Iguchi, Fumiyasu Nakamura, Haruhiko Takeda, Atsushi Takai, Ken Takahashi, Kojiro Taura,
and et al. 2020. "Dose Intensity/Body Surface Area Ratio is a Novel Marker Useful for Predicting Response to Lenvatinib against Hepatocellular Carcinoma" Cancers 12, no. 1: 49.
https://doi.org/10.3390/cancers12010049
APA Style
Eso, Y., Nakano, S., Mishima, M., Arasawa, S., Iguchi, E., Nakamura, F., Takeda, H., Takai, A., Takahashi, K., Taura, K., & Seno, H.
(2020). Dose Intensity/Body Surface Area Ratio is a Novel Marker Useful for Predicting Response to Lenvatinib against Hepatocellular Carcinoma. Cancers, 12(1), 49.
https://doi.org/10.3390/cancers12010049
